Eckert & Ziegler SECHIX:EUZD 95 Return-on-Tangible-Equity is 19.42% as of Mar. 2026, which is 21% below its 10-year median of 24.46. GuruFocus rates CHIX:EUZD with a GF Score™ of 95/100 and a GF Value™ of €16.39 (Fairly Valued). Among 756 Medical Devices & Instruments companies, Eckert & Ziegler SE ranks better than 87.04% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Eckert & Ziegler SE's annualized net income for the quarter that ended in Mar. 2026 was €41.5 Mil. Eckert & Ziegler SE's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €213.6 Mil. Therefore, Eckert & Ziegler SE's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 19.42%.
The historical rank and industry rank for Eckert & Ziegler SE's Return-on-Tangible-Equity or its related term are showing as below:
CHIX:EUZd'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 18.23 Med: 24.46 Max: 29.72
Current: 25.4
During the past 13 years, Eckert & Ziegler SE's highest Return-on-Tangible-Equity was 29.72%. The lowest was 18.23%. And the median was 24.46%.
CHIX:EUZd's Return-on-Tangible-Equity is ranked better than 87.04% of 756
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs CHIX:EUZd: 25.40
Eckert & Ziegler SE (CHIX:EUZd) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Eckert & Ziegler SE Return-on-Tangible-Equity Related Terms
Eckert & Ziegler SE Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Eckert & Ziegler SE's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eckert & Ziegler SE Return-on-Tangible-Equity Chart
CHIX:EUZD vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Eckert & Ziegler SE's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eckert & Ziegler SE Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eckert & Ziegler SE's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Eckert & Ziegler SE's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 19.42% mean?
Eckert & Ziegler SE (CHIX:EUZD) has a Return-on-Tangible-Equity of 19.42% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Eckert & Ziegler SE and its competitors. This is 21% below median its historical median of 24.46. Over the past decade, Eckert & Ziegler SE's Return-on-Tangible-Equity has ranged from 18.23 to 29.72. According to the industry distribution chart, Eckert & Ziegler SE ranks #98 out of 756 companies in the Medical Devices & Instruments industry, placing it in the top 13%.
Is Eckert & Ziegler SE's Return-on-Tangible-Equity too high?
Eckert & Ziegler SE's current Return-on-Tangible-Equity of 19.42% is 21% below median its 10-year median of 24.46. Over the past 10 years, this metric has ranged from a low of 18.23 to a high of 29.72. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.08. Eckert & Ziegler SE's value of 19.42% is 376% above this industry median. Based on the distribution chart, Eckert & Ziegler SE ranks #98 out of 756 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Eckert & Ziegler SE has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eckert & Ziegler SE's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Eckert & Ziegler SE ranks #98 out of 756 companies for Return-on-Tangible-Equity. This places Eckert & Ziegler SE in the top 13% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.08. Eckert & Ziegler SE's value of 19.42% is 376% above this benchmark. Historically, Eckert & Ziegler SE's own Return-on-Tangible-Equity has ranged from 18.23 to 29.72 over the past decade. While the company's 10-year median is 24.46 vs. the industry median of 4.08, Eckert & Ziegler SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 756 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eckert & Ziegler SE's current Return-on-Tangible-Equity of 19.42% is 376% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Eckert & Ziegler SE and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eckert & Ziegler SE's current Return-on-Tangible-Equity is 19.42%, which is 21% below median its own 10-year median of 24.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eckert & Ziegler SE stock overvalued right now?
Based on GuruFocus' analysis, Eckert & Ziegler SE (CHIX:EUZD) is currently considered Fairly Valued. The stock's GF Value™ is €16.39, compared to a current price of €15.19 — trading 7.3% below its estimated fair value. The current Return-on-Tangible-Equity is 19.42%, which is 21% below median its 10-year median of 24.46 and 376% above the Medical Devices & Instruments industry median of 4.08. Eckert & Ziegler SE's overall GF Score™ is 95/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Eckert & Ziegler SE (CHIX:EUZD), the current Return-on-Tangible-Equity is 19.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eckert & Ziegler SE (CHIX:EUZD) Overvalued in 2026?
Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued.
The current stock price of €15.19 is trading 7.3% below its estimated GF Value™ of €16.39.
GuruFocus considers Eckert & Ziegler SE to be Fairly Valued.
Key valuation signals for CHIX:EUZD:
Return-on-Tangible-Equity: 19.42% (21% below median its 10-year median of 24.46)
GF Value™: €16.39 vs. price of €15.19 (7.3% below fair value)
Industry Position: 376% above the Medical Devices & Instruments median (#98 of 756)
No single metric tells the full story. See the CHIX:EUZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
95GF Score
Get the complete analysis for CHIX:EUZD
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:EUZD has been successfully added to your 
